BR9810712A - Processo para a prevenção ou tratamento de prurido em um paciente - Google Patents

Processo para a prevenção ou tratamento de prurido em um paciente

Info

Publication number
BR9810712A
BR9810712A BR9810712-7A BR9810712A BR9810712A BR 9810712 A BR9810712 A BR 9810712A BR 9810712 A BR9810712 A BR 9810712A BR 9810712 A BR9810712 A BR 9810712A
Authority
BR
Brazil
Prior art keywords
itching
prevention
patient
treatment
compounds
Prior art date
Application number
BR9810712-7A
Other languages
English (en)
Inventor
Lawence I Kruse
An-Chi Chang
Diane L Dehaven-Hudkins
John J Farrar
Forrest Gaul
Virendra Kumar
Michael Anthony Marella
Alan L Maycock
Wei Yuan Zhang
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of BR9810712A publication Critical patent/BR9810712A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PROCESSO PARA A PREVENçãO OU TRATAMENTO DE PRURIDO EM UM PACIENTE" Compostos que tenham atividade agonista ao opióide capa, composições que os contenham e processo de usa-los como analgésicos e agentes anti-pruríticos são fornecidos. Os compostos das fórmulas têm estruturas em que X, X~ 4~, X~ 5~, X~ 7~; R~ 1~, R~ 2~, R~ 3~, R~ 4~; e Y, Z, e n são como descritos no relatório descritivo.
BR9810712-7A 1997-07-14 1998-06-19 Processo para a prevenção ou tratamento de prurido em um paciente BR9810712A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/891,833 US5763445A (en) 1996-03-08 1997-07-14 Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
PCT/US1998/012769 WO1999003468A1 (en) 1997-07-14 1998-06-19 Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith

Publications (1)

Publication Number Publication Date
BR9810712A true BR9810712A (pt) 2000-09-05

Family

ID=25398903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810712-7A BR9810712A (pt) 1997-07-14 1998-06-19 Processo para a prevenção ou tratamento de prurido em um paciente

Country Status (12)

Country Link
US (7) US5763445A (pt)
EP (1) EP0998281A1 (pt)
JP (1) JP2001510154A (pt)
KR (1) KR20010021853A (pt)
AU (1) AU725232B2 (pt)
BR (1) BR9810712A (pt)
CA (1) CA2289055A1 (pt)
IL (1) IL132388A0 (pt)
NO (2) NO996352L (pt)
NZ (2) NZ500439A (pt)
WO (1) WO1999003468A1 (pt)
ZA (1) ZA986208B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
WO1999003459A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
WO1999032096A1 (en) * 1997-12-22 1999-07-01 Alza Corporation Novel formulations for the transdermal administration of asimadoline
NZ507169A (en) 1998-04-01 2004-02-27 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
AU4572999A (en) 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
US7507545B2 (en) 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
WO2001036006A1 (en) * 1999-11-19 2001-05-25 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
WO2001070684A2 (en) * 2000-03-16 2001-09-27 Sepracor, Inc. Peptidomimetic ligands for cellular receptors and ion channels
AU8298801A (en) 2000-07-26 2002-02-05 John K Vyden Methods for treating atopic disorders
AR030128A1 (es) * 2000-08-08 2003-08-13 Daiichi Seiyaku Co Una preparacion solida altamente absorbible
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7181547B1 (en) 2001-06-28 2007-02-20 Fortinet, Inc. Identifying nodes in a ring network
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
CA2462200A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10252666A1 (de) * 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
BRPI0318278B8 (pt) 2003-05-02 2024-01-09 Cardiome Pharma Corp Compostos de éter aminocicloexílico, composição compreendendo ditos compostos, usos dos mesmos e método para modular a atividade do canal iônico em um ambiente in vitro
US7345086B2 (en) 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005113011A2 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US8263638B2 (en) 2004-11-08 2012-09-11 Cardiome Pharma Corp. Dosing regimens for ion channel modulating compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
DE102007062550A1 (de) * 2007-12-20 2009-06-25 Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts Perhydrochinoxalin-Derivate
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
CA2908963A1 (en) * 2013-05-17 2014-11-20 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Perhydroquinoxaline derivatives useful as analgesics
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6369783B2 (ja) * 2014-06-12 2018-08-08 株式会社アーダン 加水分解フィブロインを含む軟膏及びその製造方法
WO2020023873A1 (en) * 2018-07-27 2020-01-30 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat pruritus
EP3932390A1 (en) * 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065573A (en) * 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
US4098904A (en) * 1976-11-12 1978-07-04 The Upjohn Company Analgesic n-(2-aminocycloaliphatic)benzamides
US4212878A (en) * 1978-01-26 1980-07-15 The Upjohn Company Phenylacetamide derivative analgesics
DE3003303C2 (de) 1980-01-30 1984-03-08 Siemens AG, 1000 Berlin und 8000 München Verfahren zur Mattierung von hochglänzenden Epoxidharzoberflächen bei Leiterplatten
US4359476A (en) * 1981-04-09 1982-11-16 The Upjohn Company Adjacently substituted cycloalkane-amide analgesics
US4466977A (en) 1981-04-09 1984-08-21 The Upjohn Company N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics
US4360531A (en) * 1981-04-09 1982-11-23 The Upjohn Company Substituted cycloalkanes
US4438130A (en) * 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
US4463013A (en) * 1982-04-09 1984-07-31 The Upjohn Company Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4737493A (en) * 1985-07-01 1988-04-12 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
FR2592879B1 (fr) * 1986-01-13 1988-04-29 Roussel Uclaf Nouveaux derives de la decahydroquinoleine, leur procede de preparation, les intermediaires de preparation, leur application a titre de medicaments et les compositions les renfermant
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
ZA876778B (en) * 1986-09-10 1989-05-30 Du Pont Benzo-fused cycloalkane and oxa-and thia-,cycloalkane trans-1,2-diamine derivatives
US4876269A (en) 1986-09-10 1989-10-24 E. I. Du Pont De Nemours And Company Benoz-fused cycloalkane trans-1,2-diamine derivatives
EP0261842B1 (en) 1986-09-17 1990-11-22 Dr. Lo. Zambeletti S.p.A. N1-acylated-(1-(phenyl or benzyl))-1,2-ethylene diamines
GB8801304D0 (en) 1988-01-21 1988-02-17 Ici Plc Diamine compounds
FR2627491B1 (fr) 1988-02-18 1992-01-24 Roussel Uclaf Nouveaux derives du benzocyclohexane et du benzocycloheptane ainsi que leurs sels, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
US4855316A (en) * 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
GB8804104D0 (en) * 1988-02-23 1988-03-23 Glaxo Group Ltd Chemical compounds
GB8804014D0 (en) * 1988-02-23 1988-03-23 Humphreys & Glasgow Ltd Synthesis gas production
JPH02138254A (ja) * 1988-02-23 1990-05-28 Glaxo Group Ltd 複素環誘導体
PT89780A (pt) 1988-02-23 1989-10-04 Glaxo Group Ltd Processo para a preparacao de derivados da tetrahidroisoquinolina
AU616488B2 (en) 1988-03-16 1991-10-31 Dr. Lo Zambeletti S.P.A. Heterocyclic derivatives
KR900018073A (ko) * 1988-05-23 1990-12-20 추후보충 피페라진 화합물
US5021413B1 (en) 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
GB8824400D0 (en) * 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
AU626949B2 (en) * 1988-12-06 1992-08-13 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
DK626889A (da) 1988-12-16 1990-06-17 Roussel Uclaf Indanderivater, deres fremstilling samt laegemidler med indhold deraf
GB8830219D0 (en) 1988-12-23 1989-02-22 Zambeletti Spa L Novel compounds
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US4906655A (en) * 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
US4965278A (en) 1989-04-21 1990-10-23 Warner-Lambert Company 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
CA2017020A1 (en) 1989-05-18 1990-11-18 Alan Naylor Chemical compounds
GB8916395D0 (en) 1989-07-18 1989-09-06 Zambeletti Spa L Pharmaceuticals
AU1760992A (en) * 1991-05-21 1992-12-30 Dr. Lo Zambeletti S.P.A. 2-(pyrrolidinyl-1-methyl)-piperidine derivatives and their use as kappa-recept or agonists
DK0577847T3 (da) 1992-01-23 1999-06-23 Toray Industries Morphinanderivat og medicinsk anvendelse deraf
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
US5475019A (en) * 1993-02-08 1995-12-12 East Carolina University Method of treating anxiety-related disorders with 2-aminocycloaliphatic amide compounds
WO1994018165A1 (en) 1993-02-12 1994-08-18 Pfizer Inc. Sulfonamide compounds as opioid k-receptor agonists
AU686203B2 (en) 1993-07-23 1998-02-05 Toray Industries, Inc. Morphinan derivative and medicinal use
WO1996006078A1 (en) 1994-08-24 1996-02-29 Pfizer Pharmaceuticals Inc. N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
US5610271A (en) * 1995-06-07 1997-03-11 Torrey Pines Institute For Molecular Studies Kappa receptor selective opioid peptides
DE19523502A1 (de) 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
US5804595A (en) 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6057323A (en) * 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US6239154B1 (en) * 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5688955A (en) * 1996-03-08 1997-11-18 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5888494A (en) * 1996-03-12 1999-03-30 Adolor Corporation Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith
ES2236630T3 (es) * 1996-11-25 2005-07-16 Toray Industries, Inc. Agente antipruritico.
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
WO1999003459A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5849762A (en) * 1997-07-14 1998-12-15 Adolor Corporation Peripherally acting anti-pruritic opiates
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1301213B1 (en) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems

Also Published As

Publication number Publication date
KR20010021853A (ko) 2001-03-15
NZ513889A (en) 2001-09-28
ZA986208B (en) 1999-01-25
US20040220112A1 (en) 2004-11-04
US5763445A (en) 1998-06-09
WO1999003468A1 (en) 1999-01-28
CA2289055A1 (en) 1999-01-28
US20030236248A1 (en) 2003-12-25
IL132388A0 (en) 2001-03-19
AU725232B2 (en) 2000-10-12
EP0998281A1 (en) 2000-05-10
US7294647B2 (en) 2007-11-13
US6028063A (en) 2000-02-22
NZ500439A (en) 2001-10-26
JP2001510154A (ja) 2001-07-31
NO996352D0 (no) 1999-12-20
AU7980198A (en) 1999-02-10
US5981513A (en) 1999-11-09
US6960612B2 (en) 2005-11-01
NO20054249L (no) 2000-03-13
US6180623B1 (en) 2001-01-30
NO996352L (no) 2000-03-13
US20020042399A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
BR9810712A (pt) Processo para a prevenção ou tratamento de prurido em um paciente
BR9707958A (pt) Composto, composição farmacêutica, e, processo para tratar hiperalgesia em um paciente.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9909277A (pt) Compostos com atividade em receptores muscarìnicos
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR0312464A (pt) Inibidores de tirosina quinases
BR9407910A (pt) Composto composiçao farmacêutica uso do composto processo de tratamento de distúrbios no sistema nervoso central e processo de preparaçao do composto
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR0009167A (pt) Inibidores de enzima impdh
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
ES2169127T3 (es) Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco.
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
BR0014384A (pt) Compostos para o tratamento da isquémia
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
TNSN98148A1 (fr) 4-aminopyrrole (3,2-d) pyrimidines servant d'antagonistes des recepteurs de neuropeptide y
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
DK0839143T3 (da) Tetralinforbindelser med MDR-aktivitet
PT77898A (en) Process for the preparation of substituted 4-amino-methylenochromanes and 4-aminomethylenecromenes acting on the blood circulation and application thereof in the preparation of pharmaceutical compositions acting on the blood circulation
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
BR0011028A (pt) Agentes anestésicos dérmicos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36O DA LPI